Malignant Pleural Effusion Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
A malignant pleural effusion refers to a health complication involving build-up of cancer cells containing fluid between the membranes lining the lungs. It happens in almost 30 percent of all lung cancer cases. However, it can happen with other types of cancers such as lymphomas, ovarian cancer, breast cancer, and leukaemia. In case of lung cancer, malignant pleural effusion could be the sign of an advanced and complicated stage of cancer or a first sign of lung cancer.
When cancer grows into the pleural space, it results in malignant pleural effusion. This medical condition is an indication that cancer has metastasized or spread to different areas of the body. It is possible to treat malignant pleural effusion. However, it can also be turn out to be quite serious and eventually a life-threatening condition.
People with a pleural effusion may experience the following symptoms:
The global malignant pleural effusion treatment market is basically driven by the growing prevalence of pleural effusion across the globe. In addition, increased incidences of congestive heart failure, blockages of blood vessels or lymph, lung tumors, and lung injuries are likely to offer many opportunities for growth of the global malignant pleural effusion treatment market. North America is anticipated to emerge as a prominent region in the global malignant pleural effusion treatment market due to increasing prevalence of heart-related conditions and cancer.
When cancer grows in the pleural space, malignant pleural effusion is caused. In this advanced state of cancer, which is frequently the factor pertaining to decreased life expectancy of the patients, fluid is accumulated between the thin layer of chest wall and pleural tissue lining of the lung. The major type of cancer that are responsible for this condition include breast, lung, and ovarian. Generally, malignant pleural effusion is symptomatic where patients experience shortness of breath, heaviness and pain in chest, dry cough, continuous felling of unwell, and inability to do physical exercise. This fluid accumulation can be detected via a simple physical examination along with x-ray of chest and is confirmed by ultrasound imaging or by the process of thoracentesis. With the exponential rise in chronic diseases such as cancer across the world, the global malignant pleural effusion treatment market is projected to expand at a healthy CAGR during the forecast period of 2017 to 2025.
In the past few years, owing to the lucrativeness of this market where patients spend significant chunk of their income and for a long period of time, several prominent companies have invested in the research and development to find innovative treatment for malignant pleural effusion. This is the primary factors driving the surge of demand in the global malignant pleural effusion treatment market. For instance, Novartis Pharmaceuticals studying effects of “zometa” as adjuvant treatment of malignant pleural effusion due to non-small cell lung cancer, Chinese National Taiwan University Hospital developing intrapleural “bevacizumab” injection for malignant pleural effusion in lung cancer, Advantagene, Inc. in collaboration with prestigious University of Pennsylvania is developing intrapleural “AdV-tk” therapy in patients with malignant pleural effusion, Jiangsu Simcere Pharmaceutical Co., Ltd evaluating usage of endostar and cisplatin for treatment of malignant pleural effusion. Along with this, U.S. based National Cancer Institute collaboration with University of Virginia is studying role of docetaxel in treating patients with malignant pleural effusion.
Moreover, suitable reimbursement conditions laid out by several governments and the prevalence of several types of cancer is another favorable factor for the market. Conversely, high cost of these treatments is expected to hinder the growth rate of the malignant pleural effusion treatment market during the forecast period.
The global malignant pleural effusion treatment market can be segmented into North America, Europe, Asia Pacific, and rest of the world. The North America dominated by the U.S. where more than 200,000 new cases of malignant pleural effusion registered every year, according to a journal published by American Thoracic Society (ATS) in 2009. European market is dominated by the U.K., wherein lung and breast cancer together account for 50% to 65% of all malignant pleural effusion. This malignant pleural effusion treatment market can also be segmented on the basis of classes of drugs used for treatment malignancies such as alkylating agents, topoisomerase inhibitor, and antineoplastic agents.
Some of the prominent players in global malignant pleural effusion treatment market are Novartis Pharmaceuticals, Bristol Myers Squibb, and Roche Pharma AG.
This study provides a particularized anatomy according to the L.E.A.P mechanism
The regional analysis offers market assays across:
The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.
Latest Trends and Cardinal Growth Prospects
The study assists in burnishing the knowledge of the stakeholder in terms of the emerging trends. The study provides an expansive coverage on the latest developments and novel profit-yielding sources that augur well with the market. A dedicated and determined team of experts conduct an out-and-out research on diverse aspects to offer ultimate breakthroughs in the market.
Existing and Future Insights in Growth
The interfusion of ubiquitous primary and secondary research through modern tools invites perfection and accuracy in every aspect. Primary research is circumspectly conducted through exhaustive interactions and interviews of experts. These valuable opinions are then neatly inducted in the report to allow the stakeholder for reaping the benefits. A treasure of secondary data is extracted via famed paid sources, yearly estimates and statements, renowned journals, and government documents. These sources assist in creating a robust database comprising existing and subsequent growth dynamics.
Ascensions in Technology
Diverse technological advancements and cutting-edge innovations in the market have been covered in this study to assist the stakeholder in research and development activities. Recent upgrades have also been added in the study, thus helping the stakeholder to paint the strokes of growth on the canvas of the market.
The study presents a plethora of challenges and obstacles that can hinder the growth of the market to allow the stakeholder to prepare their strategies accordingly.
The world ushered in the new decade with the shadow of the COVID-19 pandemic. The outbreak has damaged the growth prospects of several businesses and has crippled the entire economy. The study is in tandem with the changing dynamics of the market due to the SARS-CoV-2 outbreak. The study focuses on the coronavirus pandemic and analyses every aspect that impacts the growth positively or negatively.
An aerial perspective of the regions covered in this study enables the stakeholder to design strategies accordingly. The 360-degree assessment of every aspect associated with growth offers information on a rainbow of growth opportunities available across the market.
The exhaustive study motivates the stakeholder to take the 'LEAP' of faith and achieve success!
This report is the key to questions such as:
What are the prominent factors that will help in reshaping the market growth?
Which trends have the potential to bring expansive growth for the market?
What are the necessary strategies to overcome the ill-effects of the COVID-19 pandemic?
Which regions will emerge as champion growth contributors for the market?
Which aspects will serve as game-changers for the market?
What are the latest innovations in the market?
Which factors will hinder the growth of the market?
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report